Drug intelligence / Profile preview

KOVIR (Sao Thai Duong Joint Stock Company)

Development stage: Unknown
Lead developer: Sao Thai Duong
Modality: Small Molecules
Administration: Oral

Overview

KOVIR (TD0069) is a traditional herbal medicine developed by Sao Thai Duong Joint Stock Company for the treatment of COVID-19. It is based on the classical Chinese medicine formula "Ren shen bai du san" (Ginseng Detoxification Powder), which is traditionally used to treat "cold conditions" or "initial plague" according to traditional medicine theory. The product is formulated as a 600 mg hard capsule containing a mixture of fine herbal powders. In clinical trials, it has been evaluated as a combination therapy alongside background treatment for COVID-19 patients who do not exhibit symptoms of acute respiratory distress, aiming to provide symptomatic relief and potentially modulate the immune response.

Brand names: KOVIR
Other names: Kovir capsuleRen shen bai du san

Beyond the preview

Go deeper on KOVIR (Sao Thai Duong Joint Stock Company).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KOVIR (Sao Thai Duong Joint Stock Company).

Explore the full profile